Multiplex or Syndromic testing....
Multiplex or Syndromic testing....
We may not yet understand , and here we are again playing catch up in that and at the forefront of a new testing in this “new norm”.
Multiplex or Syndromic testing for infectious diseases is what seems to be this new term. StageZero is shortly releasing a panel test for respiratory infections of viruses and bacteria. One could say that this is new testing capability follows into that category very well.
This is pivotal IMO, and hopefully perfect timing for the onset of the fall winter flu season with the covid pandemic running wild and the flu season approaching. Here many people may actually can be infected with Flu , and covid. Both can have similar symptoms. What do these patients really have? What is the best course of action to treat? This would be another great tool for Hospitals as well as providers of these test. Ultimately this is in the best interest of patients and doctors to rapidly seek the best course of treatment.
Seeking the best course of treatment is and can have huge savings down the road even if the test are a little higher in costs upfront. StageZero may benefit from this as they will be a provider of these tests. Time will tell.
Panel testing explained by Mayo Clinic insights.
https://news.mayocliniclabs.com/2017/10/02/syndromic-testing-infectious-diseases-part-1-respiratory-infections-hot-topic/
There have been recent FDA approvals for these types of tests under and EAU.
https://www.nasdaq.com/articles/quest-diagnostics-3-in-1-coronavirus-test-launch-well-timed-2020-10-02
https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html
I know that StageZero is primarily a cancer diagnostic company but is leveraging the diagnostic testing for covid by generating cash flow to launch Aristotle.
But here right in front of our noses we see the use and adaptation of panel testing. Panel testing TERM (Multiplex or Syndromic) is being reinforced here and now in the media and throughout the medical community and throughout the future.
As the understanding of these terms is realized and if the market really embraces this we can be in for exciting times ahead.
Is Aristotle not a panel test for Cancer? As an investor in do have to ask. Will the hospitals, health care providers along with market accept this panel test and embrace it? I believe it is actually being reinforced and supported as we move forward through this pandemic and it will ultimately help Aristotle market acceptance in the near future.
The survival rate for flu is a hell of a lot better than cancer. My bet is on Aristotle being widely accpeted going forward once launched.
Management needs to update and keep investors informed and deliver milestones.
GLTA.
Not investment advice at all. Do your own DD please.